To investigate PVEK for the treatment of pediatric ALL, we tested its efficacy against a panel of pediatric ALL patient‐derived xenograft (PDX) models representing a range of clinical subtypes and CD123 expression levels. The gene discussed is IL3RA; the disease is acute lymphoblastic leukemia.